يعرض 1 - 13 نتائج من 13 نتيجة بحث عن '"А. Д. Зикиряходжаев"', وقت الاستعلام: 0.42s تنقيح النتائج
  1. 1
    Academic Journal

    المساهمون: the research was partially funded by a grant from the non-profit organization Foundation for the Support of Scientific Research in Oncology (RakFond) to conduct a research project in the field of oncology, with funding program code 202002. Any opinions presented in this study, the data obtained and the conclusions belong to the authors and do not necessarily reflect the opinion of the RakFond., часть работы была профинансирована грантом некоммерческой организации «Фонд поддержки научных исследований в онкологии» (РакФонд) на проведение научно-исследовательского проекта в области онкологии, код программы финансирования 2020 02. Любые представленные в работе мнения, полученные данные и выводы принадлежат авторам и не обязательно отражают мнение РакФонда.

    المصدر: Research and Practical Medicine Journal; Том 11, № 4 (2024); 8-22 ; Research'n Practical Medicine Journal; Том 11, № 4 (2024); 8-22 ; 2410-1893 ; 10.17709/2410-1893-2024-11-4

    وصف الملف: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/1058/659; Sedeta ET, Jobre B, Avezbakiyev B. Breast cancer: Global patterns of incidence, mortality, and trends. Journal of Clinical Oncology. 2023;41(16 Suppl):10528–10528. doi:10.1200/jco.2023.41.16_suppl.10528; Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2024, 276 с. Доступно по: https://oncology-association.ru/wp-content/uploads/2024/08/zis-2023-elektronnaya-versiya.pdf Дата обращения: 22. 11. 2024; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long‑term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta‑analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan;19(1):27–39. doi:10.1016/s1470‑2045(17)30777‑5; Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long‑term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164–172. doi:10.1016/s0140‑6736(13)62422‑8 Erratum in: Lancet. 2019 Mar 9;393(10175):986. doi:10.1016/s0140‑6736(18)32772‑7; Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998 Aug;16(8):2672–2685. doi:10.1200/jco.1998.16.8.2672; Geng C, Chen X, Pan X, Li J. The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node‑Negative Breast Cancer after Neoadjuvant Chemotherapy : A Systematic Review and Meta‑Analysis. PLoS One. 2016 Sep 8;11(9):e0162605. doi:10.1371/journal.pone.0162605; Barrett T, Bowden DJ, Greenberg DC, Brown CH, Wishart GC, Britton PD. Radiological staging in breast cancer: which asymptomatic patients to image and how. Br J Cancer. 2009 Nov 3;101(9):1522–1528. doi:10.1038/sj.bjc.6605323; Bennett IC, Saboo A. The Evolving Role of Vacuum Assisted Biopsy of the Breast: A Progression from Fine‑Needle Aspiration Biopsy. World J Surg. 2019 Apr;43(4):1054–1061. doi:10.1007/s00268‑018‑04892‑x; van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, Loo CE, Winter‑Warnars GAO, Wiersma T, et al. Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study. Ann Surg Oncol. 2021 Jun;28(6):3243–3253. doi:10.1245/s10434‑020‑09273‑0; Vacuum Assisted Biopsy and Surgery Correlation in HER2 and TN Breast Cancer Subtypes MRI Responders After Neoadjuvant Therapy: BISUCO TRIAL NCT06371989. Доступно по: https://clinicaltrials.gov/study/NCT06371989?a=1 Дата обращения: 27. 11. 2024; Heil J, Pfob A, Sinn HP, Rauch G, Bach P, Thomas B, et al.; RESPONDER Investigators. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5‑03. Ann Surg. 2022 Mar 1;275(3):576–581. doi:10.1097/sla.0000000000004246; Максимов К. В., Багдасарова Д. В., Зикиряходжаев А. Д., Коломейцева А. А., Мазо М. Л., Суркова В. С., и др. Изучение эффективности вакуум‑аспирационной биопсии молочной железы у больных с полным клиническим ответом после неоадъювантной полихимиотерапии в комплексном лечении рака молочной железы. Research'n Practical Medicine Journal. 2023;10(4):92–103. doi:10.17709/2410‑1893‑2023‑10‑4‑8 EDN: EDOTQS; Зикиряходжаев А. Д., Волченко Н. Н., Рожкова Н. Н., Феденко А. А., Коломейцева А. А., Максимов К. В., и др. Изучение эффективности мультифокальной биопсии молочной железы у больных с полным клиническим ответом после неоадъювантной полихимиотерапии в комплексном лечении рака молочной железы. Онкология. Журнал им. П.А. Герцена. 2022;11(6):5–11. doi:10.17116/onkolog2022110615; Максимов К. В., Багдасарова Д. В., Каприн А. Д., Зикиряходжаев А. Д., Суркова В. С., Мазо М. Л., и др. Сравнение промежуточных результатов эффективности мультифокальной биопсии и вакуум‑аспирационной биопсии молочной железы в оценке патоморфологического ответа у больных раком молочной железы с полным клиническим ответом после неоадъювантной полихимиотерапи. Вопросы онкологии. 2023;69(6):1057–1064. doi:10.37469/0507‑3758‑2023‑69‑6‑1057‑1064; Криворотько П. В., Мортада В. В., Песоцкий Р. C., Артемьева А. С., Емельянов А. С., Ерещенко С. С., и др. Точность трепанобиопсии молочной железы под ультразвуковой навигацией после неоадъювантной системной терапии для прогнозирования полного патоморфологического регресса опухоли. Опухоли женской репродуктивной системы. 2022;18(3):29–39. doi:10.17650/1994‑4098‑2022‑18‑3‑29‑39; Krivorotko PS, Yerechshenko S, Emelyanov A, Busko E, Tabagua T, Novikov S, et al. 125P De‑escalation of breast cancer surgery after neoadjuvant systemic therapy in cCR/pCR patients confirmed by vacuum‑assisted biopsy (VAB) and SLNB: A first report of the prospective non‑randomized trial results. Annals of Oncology. 2022;33:S180–S180. doi:10.1016/j.annonc.2022.03.142; Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018 Aug;170(3):559–567. doi:10.1007/s10549‑018‑4801‑3; Fowler AM, Mankoff DA, Joe BN. Imaging Neoadjuvant Therapy Response in Breast Cancer. Radiology. 2017 Nov;285(2):358–375. doi:10.1148/radiol.2017170180; Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty‑year follow‑up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17;347(16):1233–1241. doi:10.1056/nejmoa022152; van Ramshorst MS, Loo CE, Groen EJ, Winter‑Warnars GH, Wesseling J, van Duijnhoven F, et al. MRI predicts pathologic complete response in HER2‑positive breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2017 Jul;164(1):99–106. doi:10.1007/s10549‑017‑4254‑0; Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, et al. Eight‑year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla ‑ Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early‑stage breast cancer: A randomized, single centre, phase III, non‑inferiority trial. Eur J Surg Oncol. 2017 Apr;43(4):672–679. doi:10.1016/j.ejso.2016.12.011; Hennigs A, Riedel F, Marmé F, Sinn P, Lindel K, Gondos A, et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat. 2016 Dec;160(3):491–499. doi:10.1007/s10549‑016‑4016‑4; Francis A, Herring K, Molyneux R, Jafri M, Trivedi S, Shaaban A, Rea DW. NOSTRA PRELIM: A non randomised pilot study designed to assess the ability of image guided core biopsies to detect residual disease in patients with early breast cancer who have received neoadjuvant chemotherapy to inform the design of a planned trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6‑10; San Antonio, TX. Philadelphia (PA): AACR. Cancer Res 2017;77(4 Suppl). doi:10.1158/1538‑7445.sabcs16‑p5‑16‑14; https://www.rpmj.ru/rpmj/article/view/1058

  2. 2
    Academic Journal

    المصدر: Creative surgery and oncology; Том 14, № 3 (2024); 235-242 ; Креативная хирургия и онкология; Том 14, № 3 (2024); 235-242 ; 2076-3093 ; 2307-0501

    وصف الملف: application/pdf

    Relation: https://www.surgonco.ru/jour/article/view/985/615; Рассказова Е.А., Зикиряходжаев А.Д., Каприн А.Д. Рецидивы и отдаленные метастазы после радикальных подкожных и кожесохранных мастэктомий с реконструкцией при раке молочной железы. Врач. 2023:34(10):58–62. DOI:10.29296/25877305-2023-10-11; Huo X., Li J., Zhao F., Ren D., Ahmad R., Yuan X., et al. The role of capecitabinebased neoadjuvant and adjuvant chemotherapy in early- stage triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21(1):78. DOI:10.1186/s12885-021-07791-y; Ортабаева Д.Р., Зикиряходжаев А. Д., Рассказова Е. А., Сарибекян Э.К., Каприн А.Д. Отдаленные онкологические результаты органосохраняющего лечения без послеоперационной лучевой терапии у больных ранним раком молочной железы старше 65 лет. Опухоли женской репродуктивной системы. 2022;18(3):24–8. DOI:10.17650/1994-4098-2022-18-3-24-28; Hong M.J., Lum S.S., Dupont E., Howard-McNatt M., Chiba A., Levine E.A., et al. Omission of radiation in conservative treatment for breast cancer: opportunity for de-escalation of care. J Surg Res. 2022;279:393– 7. DOI:10.1016/j.jss.2022.06.036; Verma R., Chandarana M., Barrett J., Anandadas C., Sundara Rajan S. Post-mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes. Cochrane Database Syst Rev. 2023;6(6):CD014463. DOI:10.1002/14651858.CD014463.pub2; Jafer F., Malki S., Akram M., Gulwarisdotter T., Karakatsanis A., Valachis A. Postmastectomy radiation therapy in breast cancer patients with micrometastatic disease in sentinel node dissection: A cohort study and meta-analysis. Clin Transl Radiat Oncol. 2024;46:100770. DOI:10.1016/j.ctro.2024.100770; Zeidan Y.H., Habib J.G., Ameye L., Paesmans M., de Azambuja E., Gelber R.D., et al. Postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes: analysis of the Breast International Group 02-98 Trial. Int J Radiat Oncol Biol Phys. 2018;101(2):316–24. DOI:10.1016/j.ijrobp.2018.01.105; Lai S.F., Huang C.S., Kuo S.H. Whether adjuvant radiotherapy is desired for postmastectomy patients with T1-T2 tumors and 1-3 positive axillary lymph nodes who received modern systemic therapy? Transl Cancer Res. 2019;8(Suppl 2):S110–4. DOI:10.21037/tcr.2018.11.18; Золотой стандарт профилактики, диагностики, лечения и реабилитации больных РМЖ. М.; 2024.; Дуадзе И.С., Каприн А.Д., Зикиряходжаев А. Д., Решетов И.В., Усов Ф.Н., Рассказова Е.А. и др. Влияние лучевой терапии на развитие осложнений при одномоментной аутологичной реконструкции молочной железы DIEP-лоскутом у больных раком молочной железы. Современная онкология. 2023:25(1):68– 72. DOI:10.26442/18151434.2023.1.202080; Munder B., Andree C., Witzel C., Fertsch S., Stambera P., Schulz T., et al. The DIEP flap as well-established method of choice for autologous breast reconstruction with a low complication rate — retrospective single-centre 10-year experience. Geburtshilfe Frauenheilkd. 2020;80(6):628–38. DOI:10.1055/a-1116-2102; Halfteck G.G., Polychronopoulou Y.E., Haque W., Weiser R., Hatch S.S., Klimberg V.S. De-escalation of post-mastectomy irradiation in hormone receptor-positive breast cancer with one to three positive nodes. Ann Surg Oncol. 2023;30(13):8335–43. DOI:10.1245/s10434-023-14155-2; Zhang N., Zhang J., Zhang H., Liu Y., Zhao W., Wang L., Individualized Prediction of survival benefit from postmastectomy radiotherapy for patients with breast cancer with one to three positive axillary lymph nodes. Oncologist. 2019;24(12):e1286–93. DOI:10.1634/theoncologist.2019-0124; Wang S., Wen G., Tang Y., Yang Y., Jing H., Wang J., et al. Effectiveness of the AJCC 8th edition staging system for selecting patients with T1- 2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions. BMC Cancer. 2020;20(1):792. DOI:10.1186/s12885-020-07267-5; Velikova G., Williams L.J., Willis S., Dixon J.M., Loncaster J., Hatton M., et al. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncol. 2018;19(11):1516– 29. DOI:10.1016/S1470-2045(18)30515-1; Ульрих Д.Г., Криворотько П.В., Брянцева Ж.В., Песоцкий Р.С., Бондарчук Я.И., Амиров Н.С. и др. Реконструктивно- пластические операции в комбинированном лечении рака молочной железы: факторы риска осложнений и реконструктивных неудач. Онкология. Журнал им. П.А. Герцена. 2024;13(3):13–9. DOI:10.17116/onkolog20241303113; https://www.surgonco.ru/jour/article/view/985

  3. 3
    Academic Journal

    المصدر: Research and Practical Medicine Journal; Том 10, № 4 (2023); 92-103 ; Research'n Practical Medicine Journal; Том 10, № 4 (2023); 92-103 ; 2410-1893 ; 10.17709/2410-1893-2023-10-4

    وصف الملف: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/958/595; https://www.rpmj.ru/rpmj/article/view/958/605; Каприн А. Д., Старинский В. В., Шахзадова А. О. Состояние онкологической ̆ помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2022, 239 c. Доступно по: https://oncology-association.ru/wp-content/uploads/2022/05/sostoyanie-onkologicheskoj-pomoshhi-naseleniyu-rossii-v-2021-godu.pdf. Дата обращения: 22.11.2023.; Bennett IC, Saboo A. The Evolving Role of Vacuum Assisted Biopsy of the Breast: A Progression from Fine-Needle Aspiration Biopsy. World J Surg. 2019 Apr;43(4):1054–1061. https://doi.org/10.1007/s00268-018-04892-x; Bennett I, de Viana D, Law M, Saboo A. Surgeon-Performed Vacuum-Assisted Biopsy of the Breast: Results from a Multicentre Australian Study. World J Surg. 2020 Mar;44(3):819–824. https://doi.org/10.1007/s00268-019-05266-7; Pistolese CA, Castrignanò A, Ricci F, Meucci R, Croce G, Mondillo M, et al. Ultrasound-Guided Vacuum-Assisted Biopsy in Small Breast: A Cost-Saving Solution. Clin Breast Cancer. 2019 Apr;19(2):e352–357. https://doi.org/10.1016/j.clbc.2018.12.002; Hennigs A, Riedel F, Marmé F, Sinn P, Lindel K, Gondos A, et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat. 2016 Dec;160(3):491–499. https://doi.org/10.1007/s10549-016-4016-4; Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012 Dec;48(18):3342–54. https://doi.org/10.1016/j.ejca.2012.05.023; Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018 Aug;170(3):559–567. https://doi.org/10.1007/s10549-018-4801-3; von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012 May 20;30(15):1796–804. https://doi.org/10.1200/jco.2011.38.8595; Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164–72. https://doi.org/10.1016/s0140-6736(13)62422-8 . Erratum in: Lancet. 2019 Mar 9;393(10175):986.; Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol. 2011 Oct;18(11):3160–3. htt ://doi.org/10.1245/s10434-011-1919-5; Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, et al. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 May;267(5):946–951. https://doi.org/10.1097/sla.0000000000002313; van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, Loo CE, Winter-Warnars GAO, Wiersma T, et al. Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study. Ann Surg Oncol. 2021 Jun;28(6):3243–3253. https://doi.org/10.1245/s10434-020-09273-0; Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB) (VAB). Доступно по: https://clinicaltrials.gov/ct2/show/NCT04293796?cond=refusal+of+breast+surgery&draw=2&rank=1; Rauch GM, Kuerer HM, Adrada B, Santiago L, Moseley T, Candelaria RP, et al. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints. Ann Surg Oncol. 2018 Jul;25(7):1953–1960. https://doi.org/10.1245/s10434-018-6481-y; Goldstein NS, Decker D, Severson D, Schell S, Vicini F, Margolis J, Dekhne NS. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2007 Oct 15;110(8):1687–96. https://doi.org/10.1002/cncr.22981; Heil J, Pfob A, Sinn HP, Rauch G, Bach P, Thomas B, et al.; RESPONDER Investigators. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03. Ann Surg. 2022 Mar 1;275(3):576581. https://doi.org/10.1097/sla.0000000000004246; Tasoulis MK, Heil J, Kuerer HM. De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer. Curr Breast Cancer Rep. 2022;14(4):135–141. https://doi.org/10.1007/s12609-022-00453-3; Heil J, Richter H, Golatta M, Sinn HP. Vacuum-Assisted Biopsy to Diagnose a Pathological Complete Response in Breast Cancer Patients After Neoadjuvant Systemic Therapy. Ann Surg. 2018 Dec;268(6):e60-e61. https://doi.org/10.1097/sla.0000000000002572; https://www.rpmj.ru/rpmj/article/view/958

  4. 4
    Academic Journal

    المصدر: Siberian journal of oncology; Том 20, № 1 (2021); 123-132 ; Сибирский онкологический журнал; Том 20, № 1 (2021); 123-132 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-1

    وصف الملف: application/pdf

    Relation: https://www.siboncoj.ru/jour/article/view/1699/835; Крылов А.В. Андрогены и РМЖ (обзор литературы). Вестник Витебского государственного медицинского университета. 2015; 14(5): 5–15.; Ni M., Chen Y., Lim E., Wimberly H., Bailey S.T., Imai Y., Rimm D.L., Liu X.S., Brown M. Targeting androgen receptor in estrogen receptornegative breast cancer. Cancer cell. 2011 Jul; 20(1): 119–31. doi:10.1016/j.ccr.2011.05.026.; Niemeier L.A., Dabbs D.J., Beriwal S., Striebel J.M., Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptorpositive tumors and in estrogen receptor- negative tumors with apocrine differentiation. Modern Pathol. 2010 Feb; 23(2): 205–12. doi:10.1038/modpathol.2009.159.; Ricciardi G.R.R., Adamo B., Ieni A., Licata L., Cardia R., Ferraro G., Franchina T., Tuccari G., Adamo V. Androgen receptor (AR), E-cadherin, and Ki67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients. PloS one. 2015; 10(6): e0128368. doi:10.1371/journal.pone.0128368.; Kasashima S., Kawashima A., Ozaki S., Nakanuma Y. Expression of 5α-reductase in apocrine carcinoma of the breast and its correlation with clinicopathological aggressiveness. Histopathology. 2012 May; 60(6B): E517. doi:10.1111/j.1365-2559.2012.04214.x.; Hu R., Dawood S., Holmes M.D., Collins L.C., Schnitt S.J., Cole K., Marotti J.D., Hankinson S.E., Colditz G.A., Tamimi R.M. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 2011 Apr 1; 17(7): 1867–74. doi:10.1158/1078-0432.CCR-10-2021.; Рябчиков Д.А., Воротников И.К., Козлов Н.А., Чхиквадзе Н.В. Андрогеновые рецепторы как фактор прогноза в различных молекулярно-биологических подтипах рака молочной железы. Сибирский онкологический журнал. 2017; 16(3): 40–45. doi:10.21294/1814-4861-2017-16-3-40-45; Ogawa Y., Hai E., Matsumoto K., Ikeda K., Tokunaga S., Nagahara H., Sakurai K., Inoue T., Nishiguchi Y. Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol. 2008 Oct; 13(5): 431–5. doi:10.1007/s10147-008-0770-6.; Gonzalez-Angulo A.M., Stemke-Hale K., Palla S.L., Carey M., Agarwal R., Meric-Berstam F., Traina T.A., Hudis C., Hortobagyi G.N., Gerald W.L., Mills G.B., Hennessy B.T. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res. 2009 Apr 1; 15(7): 2472–8. doi:10.1158/1078-0432.CCR-08-1763.; Bryan R.M., Mercer R.J., Bennett R.C., Rennie G.C., Lie T.H., Morgan F.J. Androgen receptors in breast cancer. Cancer. 1984 Dec; 54(11): 2436–40.; Macedo L.F., Guo Z., Tilghman S.L., Sabnis G.J., Qiu Y., Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006 Aug 1; 66(15): 7775–82.; Шатова Ю.С., Франциянц Е.М., Новикова И.А., Токмаков В.В., Ващенко Л.Н., Бакулина С.М., Андрейко Е.А., Кит О.И. Антиандрогенная терапия: новое направление таргетной терапии рака молочной железы? Современные проблемы науки и образования. 2017; 3: 6–6.; Agoff S.N., Swanson P.E., Linden H., Hawes S.E., Lawton T.J. Androgen Receptor Expression in Estrogen Receptor–negative Breast Cancer: Immunohistochemical, Clinical, and Prognostic Associations. Am J Clin Pathol. 2003 Nov; 120(5): 725–31.; Park S., Koo J., Park H.S., Kim J.H., Choi S.Y., Lee J.H., Park B.W., Lee K.S. Expression of androgen receptors in primary breast cancer. Ann Oncol. 2010 Mar; 21(3): 488–92. doi:10.1093/annonc/mdp510.; Крылов А.Ю., Крылов Ю.В., Янченко В.В. Экспрессия рецепторов андрогенов и С-Kit (CD117) в тройном негативном раке молочной железы. Иммунопатология. Аллергология. Инфектология. 2016; 3: 85. doi:10.14427/jipai.2016.3.85.; Rampurwala M., Wisinski K.B., O’Regan R. Role of the androgen receptor in triple-negative breast cancer. Clin Advan Hematol Oncology. 2016 Mar; 14(3): 186–93.; McNamara K.M., Moore N.L., Hickey T.E., Sasano H., Tilley W.D. Complexities of androgen receptor signalling in breast cancer. Endocrinerelated cancer. 2014 Aug; 21(4): T161–81. doi:10.1530/ERC-14-0243.; Lanzino M., De Amicis F., McPhaul M.J., Marsico S., Panno M.L., Andò S. Endogenous coactivator ARA70 interacts with ERa and modulates the functional ERalpha/AR interplay in MCF-7 cells. J Biol Chem. 2005 May 27; 280(21): 20421–30. doi:10.1074/jbc.M413576200; Peters A.A., Buchanan G., Ricciardelli C., Bianco-Miotto T., Centenera M.M., Harris J.M., Jindal S., Segara D., Jia L., Moore N.L., Henshall S.M., Birrell S.N., Coetzee G.A., Sutherland R.L., Butler L.M., Tilley W.D. Androgen receptor inhibits estrogen receptor-α activity and is prognostic in breast cancer. Cancer Res. 2009; 69(15): 6131–40. doi:10.1158/0008-5472.CAN-09-0452.; Birrell S.N., Bentel J.M., Hickey T.E., Ricciardelli C., Weger M.A., Horsfall D.J., Tilley W.D. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol. 1995 May; 52(5): 459–67. doi:10.1016/0960-0760(95)00005-k.; Fioretti F.M., Sita-Lumsden A., Bevan C.L., Brooke G.N. Revising the role of the androgen receptor in breast cancer. J Mol Endocrinol. 2014 Jun; 52(3): R257–65. doi:10.1530/JME-14-0030.; Lundström E., Carlström K., Naessen S., Söderqvist G. Dehydroepiandrosterone and/or its metabolites: possible androgen receptor antagonistic effects on digitized mammographic breast density in normal breast tissue of postmenopausal women. Horm Mol Biol Clin Investig. 2018 Aug 25; 35(1): /j/hmbci.2018.35.issue-1/hmbci-2018-0036/hmbci-2018-0036.xml. doi:10.1515/hmbci-2018-0036.; Ahram M., Mustafa E., Zaza R., Abu Hammad S., Alhudhud M., Bawadi R., Zihlif M. Differential expression and androgen regulation of microRNAs and metalloprotease 13 in breast cancer cells. Cell Biol Int. 2017; 41(12): 1345–55. doi:10.1002/cbin.10841.; Hackenberg R., Hofmann J., Hölzel F., Schulz K.D. Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells. J Cancer Res Clin Oncol. 1988; 114(6): 593–601. doi:10.1007/BF00398183.; Birrell S.N., Hall R.E., Tilley W.D. Role of the androgen receptor in human breast cancer. J Mammary gland Biol Neoplasia. 1998 Jan; 3(1): 95–103.; Lenore K. Beitel. Androgen receptor interacting proteins and coregulators table [Internet]. URL: http://androgendb.mcgill.ca/ARinteract.pdf (cited 20.11.2019).; McIlroy M., Bleach R. The divergent function of androgen receptor in breast cancer; analysis of steroid mediators and tumour intracrinology. Front Endocrinol. 2018 Oct 26; 9: 594. doi:10.3389/fendo.2018.00594.; Adair F.E., Herrmann J.B. The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann Surg. 1946 Jun; 123: 1023–35.; Culter M., Schlemenson M. Treatment of advanced mammary cancer with testosterone. JAMA. 1948 Sep 18; 138(3): 187–90.; Adair F.E. Testosterone in the treatment of breast carcinoma. Med Clin of North America. 1948 Jan; 32: 18–36. doi:10.1016/s0025-7125(16)35727-3.; Glaser R., Dimitrakakis C. Testosterone and breast cancer prevention. Maturitas. 2015; 82(3): 291–295. doi:10.1016/j.maturitas.2015.06.002.; Labrie F., Luu-The V., Labrie C., Bélanger A., Simard J., Lin S.X., Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. 2003; 24(2): 152–82. doi:10.1210/er.2001-0031.; Cochrane D.R., Bernales S., Jacobsen B.M., Cittelly D.M., Howe E.N., D'Amato N.C., Spoelstra N.S., Edgerton S.M., Jean A., Guerrero J., Gómez F., Medicherla S., Alfaro I.E., McCullagh E., Jedlicka P., Torkko K.C., Thor A.D., Elias A.D., Protter A.A., Richer J.K. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014 Jan 22; 16(1): R7. doi:10.1186/bcr3599.; Traina T.A., Miller K., Yardley D.A., Eakle J., Schwartzberg L.S., O'Shaughnessy J., Gradishar W., Schmid P., Winer E., Kelly C., Nanda R., Gucalp A., Awada A., Garcia-Estevez L., Trudeau M.E., Steinberg J., Uppal H., Tudor I.C., Peterson A., Cortes J. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018 Mar 20; 36(9): 884–890. doi:10.1200/JCO.2016.71.3495.; Gordan G.S. Calusterone in the therapy for advanced breast cancer. JAMA. 1972; 219(4): 483–490. doi:10.1001/jama.1972.03190300025008.; Goldenberg I.S., Waters N., Ravdin R.S., Ansfield F.J., Segaloff A. Androgenic therapy for advanced breast cancer in women: a report of the Cooperative Breast Cancer Group. JAMA. 1973 Mar 12; 223(11): 1267–8.; Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011 Jul; 121(7): 2750–67. doi:10.1172/JCI45014.; Lehmann B.D., Jovanović B., Chen X., Estrada M.V., Johnson K.N., Shyr Y., Moses H.L., Sanders M.E., Pietenpol J.A. Refinement of triplenegative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PloS one. 2016; 11(6): e0157368. doi:10.1371/journal.pone.0157368.; Masuda H., Baggerly K.A., Wang Y., Zhang Y., Gonzalez-Angulo A.M., Meric-Bernstam F., Valero V., Lehmann B.D., Pietenpol J.A., Hortobagyi G.N., Symmans W.F., Ueno N.T. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 1; 19(19): 5533–40. doi:10.1158/1078-0432.CCR-13-0799.; Mina A., Yoder R., Sharma P. Targeting the androgen receptor in triple-negative breast cancer: current perspectives. Onco Targets Ther. 2017 Sep 20; 10: 4675–4685. doi:10.2147/OTT.S126051.; https://www.siboncoj.ru/jour/article/view/1699

  5. 5
    Academic Journal

    المصدر: Siberian journal of oncology; Том 19, № 6 (2020); 28-37 ; Сибирский онкологический журнал; Том 19, № 6 (2020); 28-37 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2020-19-6

    وصف الملف: application/pdf

    Relation: https://www.siboncoj.ru/jour/article/view/1637/805; Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2018 (morbidity and mortality). Moscow, 2019. 250 p. (in Russian).; Сергеева Н.С., Скачкова Т.Е., Маршутина Н.В., Алексеев Б.Я., Каприн А.Д. Клиническая значимость ПСА-ассоциированных тестов в диагностике и стадировании рака предстательной железы. Онкология. Журнал им. П.А. Герцена. 2018; 7(1): 55–63. doi:10.17116/onkolog20187155-67.; Yu H., Diamandis E.P., Levesque M., Giai M., Roagna R., Ponzone R., Sismondi P., Monne M., Croce C.M. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996; 40(2): 171–8. doi:10.1007/BF01806212.; Yu H., Berkel H. Prostate-specific antigen (PSA) in women. J La State Med Soc. 1999 Apr; 151(4): 209–13.; Olsson A.Y., Bjartell A., Lilja H., Lundwall A. Expression of prostatespecific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int J Cancer. 2005; 113(2): 290–7. doi:10.1002/ijc.20605.; Nariţa D., Raica M., Anghel A., Suciu C., Cîmpean A. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast conditions. Rom J Morphol Embryol. 2005; 46(1): 41–5.; Kraus T.S., Cohen C., Siddiqui M.T. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagn Pathol. 2010 Sep 23; 5: 63. doi:10.1186/1746-1596-5-63.; Mohajeri A., Zarghami N., Pourhasan Moghadam M., Alani B., Montazeri V., Baiat A., Fekhrjou A. Prostate-specific antigen gene expression and telomerase activity in breast cancer patients: possible relationship to steroid hormone receptors. Oncol Res. 2011; 19(8–9): 375–80. doi:10.3727/096504011x13123323849636.; Zarghami N., Grass L., Sauter E.R., Diamandis E.P. Prostatespecific antigen in serum during the menstrual cycle. Clin Chem. 1997 Oct; 43(10): 1862–7.; Romppanen J., Keskikuru R., Kataja V., Eskelinen M., Kosma V.M., Savolainen K., Uusitupa M., Mononen I. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women. Br J Cancer. 1999 Mar; 79(9–10): 15837. doi:10.1038/sj.bjc.6690252.; Black M.H., Giai M., Ponzone R., Sismondi P., Yu H, Diamandis E.P. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res. 2000 Feb; 6(2): 467–73.; Dash P., Pati S., Mangaraj M., Sahu P.K., Mohapatra P.C. Serum total PSA and free PSA in breast tumors. Indian J Clin Biochem. 2011 Apr; 26(2): 182–6. doi:10.1007/s12291-011-0115-5.; Das S., Paul R., De U., Mukhopadhyay M. The lady with raised prostate specific antigen: do we need to worry? Asian Pac J Cancer Prev. 2011; 12(8): 2051–3.; Mashkoor F.C., Al-Asadi J.N., Al-Naama L.M. Serum level of prostate-specific antigen (PSA) in women with breast cancer. Cancer Epidemiol. 2013 Oct; 37(5): 613–8. doi:10.1016/j.canep.2013.06.009.; Razavi S.H., Ghajarzadeh M., Abdollahi A., Shoar S., Omranipour R. Is Serum Prostate-specific Antigen a Diagnostic Marker for Benign and Malignant Breast Tumors in Women? Int J Prev Med. 2015; 6: 15. doi:10.4103/2008-7802.151824.; Jahir E.T., Devi R., Borthakur B.B. Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour. J Clin Diagn Res. 2017 Mar; 11(3): BC13-BC16. doi:10.7860/JCDR/2017/22111.9543.; Yu H., Giai M., Diamandis E.P., Katsaros D., Sutherland D.J., Levesque M.A., Roagna R., Ponzone R., Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995 May 15; 55(10): 2104–10.; Borchert G.H., Melegos D.N., Tomlinson G., Giai M., Roagna R., Ponzone R., Sgro L., Diamandis E.P. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer. 1997; 76(8): 1087–94. doi:10.1038/bjc.1997.512.; Clendenen T.V., Ge W., Koenig K.L., Afanasyeva Y., Agnoli C., Brinton L.A., Darvishian F., Dorgan J.F., Eliassen A.H., Falk R.T., Hallmans G., Hankinson S.E., Hoffman-Bolton J., Key T.J., Krogh V., Nichols H.B., Sandler D.P., Schoemaker M.J., Sluss P.M., Sund M., Werdlow A.J., Visvanathan K., Zeleniuch-Jacquotte A., Liu M. Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. Breast Cancer Res. 2019 Mar; 21(1): 42. doi:10.1186/s13058-019-1126-z.; Hüsing A., Fortner R.T., Kühn T., Overvad K., Tjønneland A., Olsen A., Boutron-Ruault M.C., Severi G., Fournier A., Boeing H., Trichopoulou A., Benetou V., Orfanos P., Masala G., Pala V., Tumino R., Fasanelli F., Panico S., Bueno de Mesquita H.B., Peeters P.H., van Gills C.H., Quirós J.R., Agudo A., Sánchez M.J., Chirlaque M.D., Barricarte A., Amiano P., Khaw K.T., Travis R.C., Dossus L., Li K., Ferrari P., Merritt M.A., Tzoulaki I., Riboli E., Kaaks R.Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort. Clin Cancer Res. 2017; 23(15): 4181–4189. doi:10.1158/1078-0432.CCR-16-3011.; Kaaks R., Tikk K., Sookthai D., Schock H., Johnson T., Tjønneland A., Olsen A., Overvad K., Clavel-Chapelon F., Dossus L., Baglietto L., Rinaldi S., Chajes V., Romieu I., Boeing H., Schütze M., Trichopoulou A., Lagiou P., Trichopoulos D., Palli D., Sieri S., Tumino R., Ricceri F., Mattiello A., Buckland G., Ramón Quirós J., Sánchez M.J., Amiano P., Chirlaque M.D., Barricarte A., Bas Bueno-de-Mesquita H., van Gils C.H., Peeters P.H., Andersson A., Sund M., Weiderpass E., Khaw K.T., Wareham N., Key T.J., Travis R.C., Merritt M.A., Gunter M.J., Riboli E., Lukanova A. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - results from the EPIC cohort. Int J Cancer. 2014; 134(8): 1947–57. doi:10.1002/ijc.28528.; Zarghami N,, Grass L,, Diamandis E,P. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997; 75(4): 579–88. doi:10.1038/bjc.1997.101.; Guay A., Munarriz R., Jacobson J., Talakoub L., Traish A., Quirk F., Goldstein I., Spark R. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part A. Serum androgen levels in women aged 20-49 years with no complaints of sexual dysfunction. Int J Impot Res. 2004 Apr; 16(2): 112–20. doi:10.1038/sj.ijir.3901178.; Kim J., Coetzee G.A. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004 Oct 1; 93(2): 233–41. doi:10.1002/jcb.20228.; Majumder A., Singh M., Tyagi S.C. Post-menopausal breast cancer: from estrogen to androgen receptor. Oncotarget. 2017 Oct 27; 8(60): 102739–758. doi:10.18632/oncotarget.22156.; Седаков И.Е., Рогалев А.В., Садрицкая Я.В., Стеценко И.Н. Андрогены и рак молочной железы: что мы знаем? Новообразование. 2019; 11(2): 63–7. doi:10.26435/neoplasm.v11i2.276.; Gerratana L., Basile D., Buono G., De Placido S., Giuliano M., Minichillo S., Coinu A., Martorana F., De Santo I., Del Mastro L., De Laurentiis M., Puglisi F., Arpino G. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat Rev. 2018 Jul; 68: 102–110. doi:10.1016/j.ctrv.2018.06.005.; Hanamura T., Ohno K., Hokibara S., Murasawa H., Nakamura T., Watanabe H., Kaizuka M., Sawano S., Koyama H., Ito K.I. Clinical significance of serum PSA in breast cancer patients. BMC Cancer. 2019 Oct 29; 19(1): 1021. doi:10.1186/s12885-019-6256-2.; Giai M., Yu H., Roagna R., Ponzone R., Katsaros D., Levesque M.A., Diamandis E.P. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer. 1995 Sep; 72(3): 728–31. doi:10.1038/bjc.1995.401.; Radowicki S., Kunicki M., Bandurska-Stankiewicz E. Prostatespecific antigen in the serum of women with benign breast disease. Eur J Obstet Gynecol Reprod Biol. 2008 Jun; 138(2): 212–6. doi:10.1016/j.ejogrb.2007.05.023.; https://www.siboncoj.ru/jour/article/view/1637

  6. 6
    Academic Journal

    المصدر: Biomedical Photonics; Том 8, № 4 (2019); 4-10 ; 2413-9432 ; 10.24931/2413-9432-2019-8-4

    وصف الملف: application/pdf

    Relation: https://www.pdt-journal.com/jour/article/view/384/266; https://www.pdt-journal.com/jour/article/view/384/278; Lyman G.H., Somerfield M.R., Bosserman L.D., et al. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update // J Clin Oncol. – 2017. – Vol. 35(5). – P. 561–564.; Braithwaite L.R. The flow of lymph from the ileocaecal angle, and its possible bearing on the cause of duodenal and gastric ulcer // Br J Surg. – 1923. – Vol. 11. – P. 7–26.; Shaw J.H., Rumball E.M. Complications and local recurrence following lymphadenectomy // Br J Surg. – 1990. – Vol. 77. – P. 760–764.; Kissin M.W., Querci della Rovere G., Easton D., Westbury G. Risk of lymphedema following the treatment of breast cancer // Br J Surg. – 1986. – Vol. 73. – P. 580–584.; Schaafsma B.E., Verbeek F.P., Rietbergen D.D., et al. Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer // Br J Surg. – 2013. – Vol. 100(8). – P. 1037–1044.; Ballardini B., Lissidini G., Veronesi P. The indocyanine green method is equivalent to the (99m) Tc-labeled radiotracer method for identifying the sentinel node in breast cancer: A concordance and validation study // Fluorescence Imaging for Surgeons: Concepts and Applications. – 2015. – Vol. 39(12). – P. 255–266.; Giuliano A.E., Kirgan D.M., Guenther J.M., Morton D.L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer // Ann Surg. – 1994. – Vol. 220(3). – P. 391–8.; Krag D.N., Weaver D.L., Alex J.C., Fairbank J.T. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe // Surg Oncol. –1993. – Vol. 2(6). – P. 335–9.; Дашян Г.А., Криворотько П.В., Новиков С.Н. Биопсия с ных лимфатических узлов при раке молочной железы: учебнометодическое пособие для обучающихся в системе высшего и дополнительного профессионального образования. – СПб.: НИИ онкологии им. Н.Н. Петрова, 2015. – 44 с.; Старкова М.В., Зикиряходжаев А. Д., Грушина Т.И., Суркова В. Славнова Е.Н., Леонтьев А.В. Диагностическая значимость биопсии сторожевого лимфатического узла у больных ранним раком молочной железы // Онкология. Журнал им. П.А. Герцена. – 2019. – Т. 8, № 6. – С. 422–427.; Ashikaga T., Krag D.N., Land S.R., et al. Morbidity results from the NSABP-B32 trial comparing sentinel lymph node dissection versus axillary dissection // J Surg Oncol. – 2010. – Vol. 102(2). – P. 111–18.; Bergkvist L., Frisell J., Liljegren G., et al. Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer // Br J Surg. – 2001. – Vol. 88(12). – P. 1644–1648.; Edge J., Lloyd N., van der Velde C., Whittaker J. Sentinel lymph node biopsy: An audit of intraoperative assessment after intro duction of a cytotechnology service // South African Journal of Surgery. – 2015. – Vol. 53(2). – P. 47.; Ермаков А.В., Зикиряходжаев А. Д., Сарибекян Э.К., Аблицова Н.В., Усов Ф.Н. Биологическая концептуализация сторо жевого лимфатического узла (Литературный обзор) // Злокачественные опухоли. – 2016. – T. 4. – C. 5–13; Kim T., Giuliano A.E., Lyman G.H. Lymphatic mapping and s nel lymph node biopsy in early-stage breast carcinoma: a metaanalysis // Cancer. – 2006. – Vol. 106(1). – P. 4–16.; He P.S., Li F., Li G.H., et al. The combination of blue dye and radio isotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: A systematic review // BMC Cancer. 2016. – Vol. 16. – P. 107.; Motomura K., Inaji H., Komoike Y., et al. Sentinel node biopsy guided by indocyanine green dye in breast cancer patients // Jpn J Clin Oncol. – 1999. – Vol. 29(12). – P. 604–607.; Sugie T, Ikeda T, Kawaguchi A, et al. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis // Int J Clin Oncol. – 2017. – Vol. 22. – P. 11.; Портной С.М., Кузнецов А.В., Шакирова Н.М. и др. Биопсия с нального лимфатического узла с использованием флуоресцентной лимфографии у больных раком молочной железы. Методические особенности // Онкогинекология. – 2017. – № 1(21). – С. 11–18.; https://www.pdt-journal.com/jour/article/view/384

  7. 7
    Academic Journal

    المصدر: Research and Practical Medicine Journal; Том 5, № 1 (2018); 106-112 ; Research'n Practical Medicine Journal; Том 5, № 1 (2018); 106-112 ; 2410-1893 ; 10.17709/2409-2231-2018-5-1

    وصف الملف: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/249/230; Why lipofi lling. Hystory and background. Available at: http://www.lipofilling.com (accessed 07.05.15).; Venus Envy. A History of Cosmetic Surgery. By Elizabeth Haiken. Plastic Surgery Before and After. The New York Times on the Web, 1997.; Кочнева ИС. Эволюция липофилинга. От восстановления объема мягких тканей к регенеративной медицине.; Пенаев АА. Липотрансфер: острые вопросы, экспертная оценка и комментарии специалистов. Доступно по: http://www.body-jet.ru/2155135/2155136/; Rigo© G, Marchi A, Galie M, Baroni G, BnatiD, Krampera M, Pasini A, SbarbatiA. Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells. Plast Reconstr Surg. 2007 Apr 15;119 (5):1409–22; discussion 1423–4. DOI:10.1097/01.prs.0000256047.47909.71; Stevens HPJD, Willemsen JCN. Lipofilling het levend gound. Nederlands Tijdschriftvoor Plastische Chirurgle. 2013;3:97–104.; Lexer Erich. Die Freien Transplantationen, 1. Teil Mit 411 Teils Farbigen Textabbidungen. Neue Deutsche Chirurgie 26. Band Hardcover — January 1, 1919; Lyndon A. Peer, M. D. Transplantation of tissues. Vol. I, 1955.; Taek Kim. Liposuction — Then and Now. Available at: http://www.triblocal.com; Артемьев АА. Липофилинг с обогащением жира стволовыми клетками. Обзор. Пластическая хирургия и косметология. 2010;2:205–8.; Coleman SR. Facial reconturing with lipostructure. Clin Plast Surg. 1997 Apr;24 (2):347–67.; Coleman SR. Structural fat Grafting: More then Permanent Filler. Plast Reconstr Surg. 2006 Sep;118 (3 Suppl):108S-120S. DOI:10.1097/01.prs.0000234610.81672.e7; Bircoll M, Novack BH. Autologous fat transplantation employing liposuction techniques. Ann Plast Surg. 1987 Apr;18 (4):327–9.; https://www.rpmj.ru/rpmj/article/view/249

  8. 8
    Academic Journal

    المصدر: Biomedical Photonics; Том 7, № 3 (2018); 29-35 ; 2413-9432 ; 10.24931/2413-9432-2018-7-3

    وصف الملف: application/pdf

    Relation: https://www.pdt-journal.com/jour/article/view/250/193; https://www.pdt-journal.com/jour/article/view/250/250; Асеев А.В. Психологические проблемы, связанные с раком молочной железы // Клиническая медицина. – 1993. – № 3. – С. 30–34.; Awan B.A., Samargandi O.A., Alghamdi H.A., Sayegh A.A., Hakeem Y.J., Merdad L., Merdad A.A. The desire to utilize postmastectomy breast reconstruction in Saudi Arabian women. Predictors and barriers // Saudi Med J. – 2015. – Vol. 36(3). – P. 304–309.; Morrow M., Li Y., Alderman A.K., Jagsi R., Hamilton A.S., Graff J.J., Hawley S.T., Katz S.J. Access to breast reconstruction after mastectomy and patient perspectives on reconstruction decision making // JAMA Surg. – 2014. – Vol. 149(10). – P. 1015–1021.; Решетов И.В., Чиссов В.И. Пластическая и реконструктивная микрохирургия в онкологии. – М.: ООО РИФ, 2001. – 200 с.; Филоненко Е.В., Сарибекян Э.К., Иванова-Радкевич В.И. Возможности интраоперационной фотодинамической терапии в лечении местнораспространенного рака молочной железы // Biomedical Photonics. – 2016. – Т. 5, № 1. – С. 9–14.; Chalnot P., Michon J. Le dedoublement du sein restant // Ann Chir Plast. – 1958. – Vol. 3. – P. 35.; Семиглазов В.Ф. Минимальный рак молочной железы. – Ленинград: Медицина, 1992. – 276 с.; Шарова О.Н., Васильев С.А., Буйков В.А., Важенин А.В. Реконструкция молочной железы как наиболее конструктивный механизм психологической защиты у женщин после радикального лечения рака молочной железы // Анналы пластической, реконструктивной и эстетической хирургии. – 2001. –№ 1. – С. 43–49.; Бурлаков А.С. Восстановительная хирургия в лечении больных раком молочной железы // Вестник Московского онкологического общества. – 2002. – № 9. – С. 1–8.; Omranipour R., Bobin J.Y., Esouyeh M. Skin Sparing Mastectomy and Immediate Breast Reconstruction (SSMIR) for early breast cancer: eight years single institution experience // World J Surg Oncol. – 2008. – Vol. 6. – P. 43.; Pacifico M.D., See M.S., Cavale N., Collyer J., Francis I., Jones M.E., Hazari A., Boorman J.G., Smith R.W. Preoperative planning for DIEP breast reconstruction: early experience of the use of computerised tomography angiography with VoNavix 3D software for perforator navigation // J Plast Reconstr Aesthet Surg. – 2009. – Vol. 62(11). – P. 1464–1469.; Rietjens M., De Lorenzi F., Venturino M., Petit J.Y. The suspension technique to avoid the use of tissue expanders in breast reconstruction // Ann Plast Surg. – 2005. – Vol. 54(5). — P. 467–470.; Cumberland V.H. A preliminars report on the use of prefabricated nylon weave in the repair of ventral hernia // Med J Aust. – 1952. — Vol. 1(5). – P. 143–144.; Scales J.T. Discussion on metals and synthetic materials in relation to soft tissues: tissue reaction to synthetic materials // Proc R Soc Med. – 1953. – Vol. 46. – P. 647.; Разумовский А.Ю., Смирнова С.В. Использование имплантационных материалов для пластики диафрагмы у новорожденных // Хирургия. – 2012. – № 11. – C. 90–95.; Chun Y.S., Verma K., Rosen H., Lipsitz S., Morris D., Kenney P., Eriksson E. Implant-based breast reconstruction using acellular dermal matrix and the risk of postoperative complications // Plast Reconstr Surg. – 2010. – Vol. 125(2). – P. 429–436.; Lanier S.T., Wang E.D., Chen J.J., Arora B.P., Katz S.M., Gelfand M.A., Khan S.U., Dagum A.B., Bui D.T. The effect of acellular dermal matrix use on complication rates in tissue expander/implant breast reconstruction // Ann Plast Surg. – 2018. – Vol. 64(5). – P. 674–678.; Glasberg S.B., Light D. AlloDerm and Strattice in breast reconstruction: a comparison and techniques for optimizing outcomes // Plast Reconstr Surg. – 2012. – Vol. 129(6). – P. 1223–1233.; Hoppe I.C., Yueh J.H., Wei C.H., Ahuja N.K., Patel P.P., DatiashviliR.O. Complications Following Expander/Implant Breast Reconstruction Utilizing Acellular Dermal Matrix: A Systematic Review and Meta-Analysis // Open Access Journal of Plastic Surgery. – 2013. – Vol. 11. – P. 417–428.; Salzberg C.A. Nonexpansive immediate breast reconstruction using human acellular tissue matrix graft (AlloDerm) // Ann Plast Surg. – 2006. – Vol. 57(1). – P. 1–5.; Seth A.K., Hirsch E.M., Fine N.A., Kim J.Y. Breast Reconstruction – Current Perspectives and State of the Art Techniques. Utility of acellular dermis-assisted breast reconstruction in the setting of radiation: a comparative analysis // Plast Reconstr Surg. – 2012. – Vol. 130(4). – P. 750–758.; Colwell A.S., Damjanovic B., Zahedi B., Medford-Davis L., Hertl C., Austen W.G.Jr. Retrospective review of 331 consecutive immediate single-stage implant reconstructions with acellular dermal matrix: indications, complications, trends, and costs // Plast Reconstr Surg. – 2011. – Vol. 128(6). – P. 1170–1178.; Nahabedian M.Y. AlloDerm performance in the setting of prosthetic breast surgery, infection, and irradiation // Plast Reconstr Surg. – 2009. – Vol. 124(6). – P. 1743–1753.; Weichman K.E., Wilson S.C., Weinstein A.L., Hazen A., Levine J.P., Choi M., Karp N.S. The use of acellular dermal matrix in immediate two-stage tissue expander breast reconstruction // Plast Reconstr Surg. – 2012. – Vol. 129(5). – P. 1049–1058.; Weichman К., Disa J. Prosthetic Breast Reconstruction with Acellular Dermal Matrix // Breast Reconstruction – Current Perspectives and State of the Art Techniques. – chapter 4. – p. 67–80. doi:10.5772/56331; Breuing K.H., Colwell A.S. Inferolateral AlloDerm hammock for implant coverage in breast reconstruction // Ann Plast Surg. – 2007. – Vol. 59(3). – P. 250–255.; Breuing K.H., Warren S.M. Immediate bilateral breast reconstruction with implants and inferolateral AlloDerm slings // Ann Plast Surg. – 2005. – Vol. 55(3). – P. 232–239.; Parks J.R., Hammond S.E., Walsh W.A., Adams R.L., Chandler R.G., Luce E.A. Human acellular dermis versus no acellular dermis in tissue expansion breast reconstruction // Plast Reconstr Surg. – 2012. – Vol. 130(4). – P. 736–740.; Vardanian A.J., Clayton J.L., Roostaeian J., Shirvanian V., Da Lio A., Lipa J.E., Crisera C., Festekjian J.H. Comparison of implant-based immediate breast reconstruction with and without acellular dermal matrix // Plast Reconstr Surg. – 2011. – Vol. 128(5). – P. 403–410.; Baxter R.A. Intracapsular allogenic dermal grafts for breast implant-related problems // Plast Reconstr Surg. – 2003. – Vol. 112(6). – P. 1692–1696.; Becker S., Saint-Cyr M., Wong C., Dauwe P., Nagarkar P., Thornton J.F., Peng Y. AlloDerm versus DermaMatrix in immediate expander-based breast reconstruction: a preliminary comparison of complication profiles and material compliance // Plast Reconstr Surg. – 2009. – Vol. 123(1). – P. 1–6.; Bindingnavele V., Gaon M., Ota K.S., Kulber D.A., Lee D.J. Use of acellular cadaveric dermis and tissue expansion in postmastectomy breast reconstruction // J Plast Reconstr Aesthet Surg. – 2007. – Vol. 60(11). – P. 1214–1218.; Surgeons ASoP. American Society of Plastic Surgeons 2011 Statistics, 2011. Available at: http:// www.plasticsurgery.org/ News-and-Resources/2011-Statistics.html; Spear S.L., Parikh P.M., Reisin E., Menon N.G. Acellular dermisassisted breast reconstruction // Aesthetic Plast Surg. – 2008. – Vol. 32(3). – P. 418–425.; Liu A.S., Kao H.K., Reish R.G., Hergrueter C.A., May J.W.Jr., Guo L. Postoperative complications in prosthesis-based breast reconstruction using acellular dermal matrix // Plast Reconstr Surg. – 2011. – Vol. 127(5). – P. 1755–1762.; Antony A.K., McCarthy C.M., Cordeiro P.G., Mehrara B.J., Pusic A.L., Teo E.H., Arriaga A.F., Disa J.J. Acellular human dermis implantation in 153 immediate two-stage tissue expander breast reconstructions: determining the incidence and significant predictors of complications // Plast Reconstr Surg. – 2010. – Vol. 125(6). – P. 1606–1614.; Gamboa-Bobadilla G.M. Implant breast reconstruction using acellular dermal matrix // Ann Plast Surg. – 2006. – Vol. 56(1). – P. 22–25.; Topol B.M., Dalton E.F., Ponn T., Campbell C.J. Immediate singlestage breast reconstruction using implants and human acellular dermal tissue matrix with adjustment of the lower pole of the breast to reduce unwanted lift // Ann Plast Surg. – 2008. – Vol. 61(5). – P. 494–499.; https://www.pdt-journal.com/jour/article/view/250

  9. 9
    Academic Journal

    المصدر: Malignant tumours; Том 8, № 2 (2018); 43-49 ; Злокачественные опухоли; Том 8, № 2 (2018); 43-49 ; 2587-6813 ; 2224-5057

    وصف الملف: application/pdf

    Relation: https://www.malignanttumors.org/jour/article/view/515/369; Каприн А. Д., Старинский В. В., Петрова Г. В. Состояние онкологической помощи населению России в 2016 году. Москва, 2017. с. 236.; Radovan C. Breast reconstruction after mastectomy using the temporary expander. Plast. Reconstr. Surg. 1982. No. 69. P. 195–208.; Габка К., Бомерт Х. Пластическая и реконструктивная хирургия молочной железы. Пер. с англ. Под общ. ред. Н. О. Миланова. Москва, 2010. 360 с.; Рассказова Е. А. Современные принципы лечения рака молочной железы. Врач. 2017. № 5. С. 7–8.; Ronert M. A., Hofheinz H., Manassa E. et al. The beginning of a new era in tissue expansion: self filling osmotic tissue expander – four year clinical experience. Plast. Reconstr. Surg. 2004. Vol. 114. P. 1025–1031.; Ronert M. A., Hofheinz H., Olbrisch R. R. The beginning of a new era: self-filling tissue expander for defect coverage in a 3-year-old boy with a retroauricular nevus. Plast. Reconstr. Surg. 2003. Vol. 112 (1). P. 189–191.; Chummun S. et al. The osmotic tissue expander: A 5-year experience. J. Plast. Reconstr. Aesthetic Surg. 2010. doi:10.1016/j.bjps. 2010.02.002.; Gronovich Y. et al. Osmotic Tissue Expander – Experience in Ten Consecutive Pediatric Cases. Plastic Reconstructive Surgery. 2010. doi:10.1097/01.prs.0000388805.53479.59.; Wollina U., Bayyoud Y. Reconstruction of a large scalp defect by the sequential use of dermal substitute, self-filling osmotic tissue expander and rotational flap. J. Cutaneous and Aesthetic Surgery. 2010. Vol. 3. Issue 2. doi:10.4103/0974-2077.69023.; Gronovich Y. et al. Reconstruction with an Osmotic Tissue Expander in Pediatric Patients. Plast. Reconstr. Surg. 2012. Vol. 129 (5). P. 863–865. doi:10.1097/PRS.0b013.31824.9f4.; Царев О. Н., Гольдман Ю. И. Хирургическая реабилитация больных после радикального лечения рака молочной железы. Тюменский медицинский журнал. 2014. Т. 16. № 4. C. 48–49.; Мавроди Т. В., Исмагилов А. Х. Осложнения при реконструктивно-пластических операциях на молочной железе. Анналы пластической, реконструктивной и эстетической хирургии. 2010. № 4. C. 106–107.; Добрякова О. Б., Добряков Б. С., Аршакян В. А., Гулев В. С. Реконструкция молочной железы с использованием экспандеров. Собственный опыт. Анналы пластической, реконструктивной и эстетической хирургии. 2012. № 4. C. 36–44.; https://www.malignanttumors.org/jour/article/view/515

  10. 10
    Academic Journal

    المصدر: Research and Practical Medicine Journal; Том 4, № 2 (2017); 13-22 ; Research'n Practical Medicine Journal; Том 4, № 2 (2017); 13-22 ; 2410-1893 ; 10.17709/2409-2231-2017-4-2

    وصف الملف: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/182/178; Atalay C, Kinas V, Celebioglu S. Analysis of patients with phylloides tumor of the breast. Turkish J Surg. 2014; 30 (3): 129–132. DOI:10.5152/UCD.2014.2719; Волченко А. А., Пак Д. Д., Усов Ф. Н., Фетисова Е. Ю., Ефанов В. В. Гигантская листовидная опухоль молочной железы. Онкохирургия. 2012; 4 (2): 77–80.; Müller J. Über den feineren Ban und die Formen der Krankaften Geschwulste. Berlin: G Reiner. 1838; 1: 54–57.; World Health Organization Histological typing of breast tumors. Tumori. 1982; 68: 181–198.; Liang М, Ramaswamy В, Patterson С, McKelvey MT, Gordillo G, Nuovo GJ, et al. Giant breast tumors: Surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature. World J Surg Oncol. 2008; 6: 117. DOI:10.1186/1477–7819–6-117; Tavassoli FA, Devilee P.Pathology and genetics of tumours of the breast and female genital organs. In: World Health Organization Classification of Tumours, IARC Press, Lyons 2003. p. 99.; Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer. 1993; 71 (10): 3020–3024. DOI:10.1002/1097–0142 (19930515)71:103.0.CO;2-G; Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, et al. Clinicopathologic features and long-term outcom es of 2 93phyllodes tum ors of the breast. Ann Surg Oncol 2007; 14 (10): 2961–2970. DOI:10.1245/s10434–007–9439-z; Calhoun K, Lawton TJ, Kim JM, et al. Phyllodes tumors. In: Diseases of the breast. Harris J, Lippman ME, Osborne CK, Morrow M (eds). Lippincott Williams and Wilkins, 2010, p.781.; Telli ML, Horst KC, Guardino AE, Dirbas FM, Carlson RW. Phyllodes tumors of the breast: natural history, diagnosis, and treatment. J Natl Compr Canc Netw. 2007 Mar; 5 (3): 324–330. DOI:10.6004/jnccn.2007.0027; Carter BA, Page DL. Phyllodes tumor of the breast: local recurrence versus metastatic capacity. Hum Pathol. 2004; 35 (9): 1051–1052. DOI:10.1016/j.humpath.2004.08.001; Reinfuss M, Mituś J, Duda K, Stelmach A, Ryś J, Smolak K. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer. 1996; 77 (5): 910–916. DOI:10.1002/(SICI)1097–0142 (19960301)77:53.0.CO;2–6; National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Availavle at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016); Jacklin RK, Ridgway PF, Ziprin P, Healy V, Hadjiminas D, Darzi A. Optimising preoperative diagnosis in phyllodes tumour of the breast. J Clin Pathol. 2006; 59 (5): 454–459. DOI:10.1136/jcp.2005.025866; Jang JH, Choi MY, Lee SK, Kim S, Kim J, Lee J, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Ann Surg Oncol. 2012 Aug; 19 (8): 2612–7. DOI:10.1245/s10434–012–2307–5; Tavassoli FA, Devilee P.Genetics of tumours of the breast and female genital organs. In: World Health Organization Classification of Tumours, IARC Press, Lyons 2003. p. 99.; Kuijper A, Buerger H, Simon R, Schaefer KL, Croonen A, Boecker W, et al. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol. 2002; 197 (5): 575–581. DOI:10.1002/path.1161; Wiratkapun C, Piyapan P, Lertsithichai P, Larbcharoensub N. Fibroadenoma versus phyllodes tumor: distinguishing factors in patients diagnosed with fibroepithelial lesions after a core needle biopsy. Diagn Interv Radiol. 2014 Jan-Feb; 20 (1): 27–33. DOI:10.5152/dir.2013.13133; Летягин В. П., Ермилова В. Д., Воротников И. К. Злокачественные неэпиелиальные опухоли молочных желез. Вестник РОНЦ им. Н. Н. Блохина РАМН. 1996; 7 (3): 57–59; Волченко А. А., Пак Д. Д., Усов Ф. Н., Фетисова Е. Ю. Гигантская листовидная опухоль молочной железы: клиническое наблюдение. Опухоли женской репродуктивной системы. 2012; 2: 27–29.; Spitaleri G, Toesca A, Botteri E, Bottiglieri L, Rotmensz N, Boselli S, et al. Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Crit Rev Oncol Hematol. 2013 Nov; 88 (2): 427–36. DOI:10.1016/j.critrevonc.2013.06.005; Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000; 89 (7): 1502–1511.; Ward RM, Evans HL. Cystosarcoma phyllodes: a clinicopathologic study of 26 cases. Cancer. 1986; 58 (10): 2282–2289. DOI:10.1002/1097–0142 (19861115)58:103.0.CO;2–2; Cohn-Cedermark G, Rutqvist LE, Rosendahl I, Silfverswärd C. Prognostic factors in cystosarcoma phyllodes. A clinicopathologic study of 77 patients. Cancer. 1991; 68 (9): 2017–2022. DOI:10.1002/1097–0142 (19911101)68:93.0.CO;2-V; Norris HJ, Taylor HB. Relationship of histologic features to behavior of cystosarcoma phyllodes. Analysis of ninety-four cases. Cancer. 1967; 20 (12): 2090–2099. DOI:10.1002/1097–0142 (196712)20:123.0.CO;2-L; Hawkins RE, Schofield JB, Fisher C, Fisher C, Wiltshaw E, McKinna JA. The clinical and histologic criteria that predict m etastases from cystosarcom a phyllodes. Cancer 1992; 69 (1): 141–147. DOI:10.1002/1097–0142 (19920101)69:13.0.CO;2–1; Fajdić J, Gotovac N, Hrgović Z, Kristek J, Horvat V, Kaufmann M. Phyllodes tumors of the breast diagnostic and therapeutic dilemmas. Onkologie. 2007 Mar; 30 (3): 113–118. DOI:10.1159/000099580; Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer 2006; 107 (9): 2127–2133. DOI:10.1002/cncr.22228; Barth RJ Jr, Wells WA, Mitchell SE, Cole BF. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Ann Surg Oncol. 2009 Aug; 16 (8): 2288–2294. DOI:10.1245/s10434–009–0489–2; Kapiris I, Nasiri N, A’Hern R, Healy V, Gui GP. Outcome and predictive factors of local recurrence and distant m etastases following prim ary surgical treatm ent of highgrade malignant phyllodes tumours of the breast. Eur J Surg Oncol. 2001; 27 (8): 723–730. DOI:10.1053/ejso.2001.1207; Parker SJ, Harries SA. Phyllodes tumours. Postgrad Med J. 2001 Jul; 77 (909): 428–435. DOI:10.1136/pmj.77.909.428; Belkacémi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magné N, Malard Y, et al. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys 2008; 70 (2): 492–500. DOI:10.1016/j.ijrobp.2007.06.059; Pezner RD, Schultheiss TE, Paz IB. Malignant phyllodes tumor of the breast: local control rates with surgery alone. Int J Radiat Oncol Biol Phys. 2008 Jul 1; 71 (3): 710–713. DOI:10.1016/j.ijrobp.2007.10.051; Gnerlich JL, Williams RT, Yao K, Jaskowiak N, Kulkarni SA. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998–2009. Ann Surg Oncol. 2014 Apr; 21 (4): 1222–30. DOI:10.1245/s10434–013–3395–6; Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, Lopez-Basave HN, Gallardo D, Hortobagyi GN, et al. Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free surviv al of m alignant phyllodes tumors of the breast. Breast J. 2007 Nov-Dec; 13 (6): 551–556. DOI:10.1111/j.1524–4741.2007.00510.x; Burton GV, Hart LL, Leight GS Jr, Iglehart JD, McCarty KS Jr, Cox EB. Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. Cancer. 1989; 63 (11): 2088–2092. DOI:10.1002/1097–0142 (19890601)63:113.0.CO;2-C; Sapino A, Bosco M, Cassoni P, Castellano I, Arisio R, Cserni G, et al. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod Pathol 2006; 19 (4): 599–606. DOI:10.1038/modpathol.3800574; Tse GM, Lee CS, Kung FY, Scolyer RA, Law BK, Lau TS, et al. Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol. 2002; 118 (4): 522–526. DOI:10.1309/D206-DLF8-WDNC–XJ8K; Confavreux C, Lurkin A, Mitton N, Blondet R, Saba C, Ranchère D, et al. Sarcomas and malignant phyllodes tumours of the breast — a retrospective study. Eur J Cancer. 2006 Nov; 42 (16): 2715–2721. DOI:10.1016/j.ejca.2006.05.040; https://www.rpmj.ru/rpmj/article/view/182

  11. 11
    Academic Journal

    المصدر: Research and Practical Medicine Journal; Том 4, № 1 (2017); 63-67 ; Research'n Practical Medicine Journal; Том 4, № 1 (2017); 63-67 ; 2410-1893 ; 10.17709/2409-2231-2017-4-1

    وصف الملف: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/174/171; Зикиряходжаев А.Д., Волченко А.А., Ермощенкова М.В., Сухотько А.С. Алгоритм выбора реконструктивно-пластических операций у больных раком молочной железы. Поволжский онкологический вестник. 2015; 3: 38–44.; Кочнева И.С. Эволюция липофилинга. От восстановления объема мягких тканей к регенеративной медицине.; Why lipofilling. Hystory and background.; Khouri RK, Rigotti G, Khouri RK Jr, Cardoso E, Marchi A, Rotemberg SC, et al. Tissue-engineered breast reconstruction with Brava-assisted fat grafting: a 7-year, 488-patient, multicenter experience. Plast Reconstr Surg. 2015 Mar;135 (3):643–58. doi:10.1097/PRS.0000000000001039; Chirappapha P, Rietjens M, De Lorenzi F, Andrea M, Hamza A, Petit J-Y, et al. Evaluation of Lipofilling Safety in Elderly Patients with Breast Cancer. Plast Reconstr Surg Glob Open. 2015 Aug 10;3 (7): e441. doi:10.1097/GOX.0000000000000411; Venus Envy. A History of Cosmetic Surgery. By Elizabeth Haiken. Plastic Surgery Before and After. The New York Times on the Web, 1997.; Stevens HPJD, Willemsen JCN. Lipofilling het levend gound. Nederlands Tijdschrift voor Plastische Chirurgle. 2013; 3: 97–104.; Lexer E. Die Freien Transplantationen, 1. Teil Mit 411 Teils Farbigen Textabbidungen. Neue Deutsche Chirurgie 26. Band Hardcover — January 1, 1919.; Peer LA. Transplantation of tissues. Vol. I, 1955.; Taek Kim. Liposuction — Then and Now. Available at: http://www.triblocal.com; Coleman SR. Structural fat grafting: more then permanent filler. Plast Reconstr Surg. 2006 Sep;118 (3 Suppl):108S-120S. DOI:10.1097/01.prs.0000234610.81672.e7; Bircoll M, Novack BH. Autologous fat transplantation employing liposuction techniques. Ann Plast Surg. 1987 Apr; 18 (4): 327–9.; Rigotti G, Marchi A, Galie M, Baroni G, Bnati D, Krampera M, et al. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg. 2007 Apr 15;119 (5):1409–22; discussion 1423–4. DOI:10.1097/01.prs.0000256047.47909.71; https://www.rpmj.ru/rpmj/article/view/174

  12. 12
    Academic Journal

    المصدر: Research and Practical Medicine Journal; Том 3, № 1 (2016); 39-45 ; Research'n Practical Medicine Journal; Том 3, № 1 (2016); 39-45 ; 2410-1893 ; 10.17709/2409-2231-2016-3-1

    وصف الملف: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/123/127; Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). М., 2016.; Зикиряходжаев А. Д., Рассказова Е. А. Онкопластические резекции при раке молочной железы. Онкология. Журнал им. П. А. Герцена. 2015; 4: 80–84.; Малыгин С. Е., Малыгин Е. Н., Рускова Н. Г. Реконструктивно-пластические вмешательства при раке молочной железы. Новые стандарты и перспективы. Практическая онкология. 2010; 11 (4): 253–257.; Florian Fitzal, Peter Schrenk (Eds.) Oncoplastic breast surgery: A Guide to Clinical Practice, 2010.; Хамди М., Хаммонд Д., Нахаи Ф. Вертикальная маммопластика. 2012.; Wise R. J. A preliminary report on a method of planning the mammaplasty. Plast Reconstr Surg. 1956; 17 (5): 357–375.; Clough K. B., Kaufman G. J., Nos C., et al. Improving breast cancer surgery: a classification and quadrant per quadrant atlas for oncoplastic surgery. Ann Surg Oncol. 2010; 17 (5): 1375– 1391.; Hammond D. C. Short scar periareolar inferior pedicle reduction (SPAIR) mammoplasty. Plast Reconstr Surg. 1999; 103 (3): 890–901.; https://www.rpmj.ru/rpmj/article/view/123

  13. 13
    Academic Journal

    المصدر: Malignant tumours; № 3 (2016); 67-79 ; Злокачественные опухоли; № 3 (2016); 67-79 ; 2587-6813 ; 2224-5057

    وصف الملف: application/pdf

    Relation: https://www.malignanttumors.org/jour/article/view/263/235; Blakeslee D. B., Becker G. D., Simpson G. T. Lymphoscintigraphy of the neck. Otolaryngol Head and Neck.//Surg. Oncol. – 1985. – V. 93. – P. 361–365.; Krag D. N., Weaver D. L., Alex J. C., Fairbank J. T. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe //Surg. Oncol. – 1993. – V. 101. – P. 335–339.; Alazraki N. P., Styblo Т., Grant S. F., Cohen C., Larsen T. Aarsvold J. N. Sentinel node staging of early breast cancer using lymphoscintigraphy and the intraoperative gamma- detecting probe // Semin. Nucl. Med. – 2000. – V. 30. – P. 56–64.; Ames F., Laronga C., Ross M., Alderfer J. Tumor Location and Nodal Drainage Patterns on Lymphoscintigraphy Are Predictors of Axillary Sentinel Lymph Node Status //J. of ASCO. – 2001. – V.20. – P. 40–43.; Романов И. С., Оджарова А. А., Ротин Д. Л., Нечушкин М. И. «Сторожевые» лимфатические узлы при плоскоклеточном раке головы и шеи. // Вестник оториноларингологии. – 2007. – № 6. – С. 14–17. Romanov I. S., Odzharova A. A. Rotin D. L., Nechushkin M. I. Sentinel lymph nodes in squamous cell carcinoma of the head and neck. // Herald of otorhinolaryngology. – 2007. – № 6. – p. 14–17.; Kern K. A., Rosenberg R. J. Preoperative lymphoscintigraphy during lymphatic mapping for breast cancer: improved sentinel node imaging using subareolar injection of technetium 99m sulfur colloid. // J Am. Coll. Surg. – 2000. – V. 191. – P. 479–489.; Прилепо Ю. В. «Способ диагностики метастазирования при раке молочной железы или меланоме». // Патент РФ – № 2195871. – 2003. Prilepo Y. V. A method of diagnosis for metastatic breast cancer or melanoma.» // Patent of Russia – № 2195871. – 2003.; Tu Weixia, Denizot B. Synthesis of small-sized rhenium sulfide colloidal nanoparticles. // J. Сolloid Interface Sci. – 2007. – V. 310. – P. 167–170.; Khalkhali I., Cutrone J. A., Mena I. J. Scintimammography: the complementary role of Tc‑99m Sestamibi prone breast imaging for the diagnosis of breast carcinoma // Radiology. – 1995. – V.196. – P. 421–426.; Tsopelas Ch. 99mTc-Labeled and Unlabeled Antimony Trisulfide and Rhenium Sulfide Colloids Intended for Lymphoscintigraphic Application. // J. Nucl. Med. – 2001. – V. 42. – P 460–466.; Weiss M., Kunte Ch., Schmid R. A., Konz B. Sentinel node mapping in patients with malignant melanoma using melanoma Tc‑99m colloidal rhenium sulfide. // J. Clin. Nucl. Med. – 2003. – V 28. – P. 379–384.; Mochiki E., Kuwano H., Kamiyama. Y., Aihara R., Nakabayashi T., Endo K. Sentinel lymph node mapping with technetium‑99m colloidal rhenium sulfide in patients with gastric carcinoma .// Amer. J. Surg. – 2006. – 191. – P. 465–469.; N ez, Eutimio Gustavo Fern ndez / Faintuch, Bluma Linkowski / Teodoro, Rodrigo / Wiecek D. P., Martinelli J. R., Da Silva N. G., Castanheira C. E., Pasqualini R. Influence of colloid particle profile on sentinel lymph node uptake. //J. Nucl. Med. Biol. – 2009. – V 36. – P. 741–747.; Jimenez I. R., Roca M., Vega E., Garc a M. L., Benitez A., Baj n M. //.Particle sizes of colloids to be used in sentinel lymph node radiolocalization. // J. Nucl.Med. Commun. – 2008. – V 29 – P. 166–172.15. Bensimhon L., M tay T., Guilhot J., Perdrisot R. // Influence of temperature on the radiochemical purity of 99mTc-colloidal rhenium sulfide for use in sentinel node localization. // J. Nucl. Med. Commun. – 2008. – V 29. – P. 1015–1020.; Свешников К. А., Русейкин Н. С. Скорость движения лимфы в здоровой и травмированной конечностях. // Современные проблемы науки и образования. – 2008. – № 2 – С. 22–28. Sveshnikov K. A., Ruseykin N. S. The speed of lymph movement in the healthy and the injured limbs. // Modern problems of science and education. – 2008. – № 2 – p. 22–28.; Панченков Р. Т., Ярема И. В., Сильманович Н. Н. Лимфостимуляция. М.: Медицина. 1986. 237 с. Panchenkov R. T., Yarema I. V., Silmanovich N. N., Lymphostimulation. M .: Medicine. 1986. p. 237.; Koizumi M., Nomura E., Yamada Y. et al. Sentinel node detection using 99mTc-rhenium sulphide colloid in cancer patients: evaluation of 1 day and 2 day protocols and a dose-finding study. Nucl Med Commun 2003; 24: 663–670.; Mirzaei S., Rodrigues M., Hoffmann B. et al. Sentinel lymph node detection with large human serum albumin colloid particles in breast cancer. Eur.J.Nucl.Med.Mol.Imaging 2003; 30: 874–878.; Kr zov H., Wald M., Strnad P. et al. Detection of the sentinel node in breast carcinoma using method of a single subcutaneous injection of radiopharmaceutical. Neoplasma 2004; 51: 44–48.; https://www.malignanttumors.org/jour/article/view/263